Key Highlights
- Cristiana Guiducci, Ph.D., named Chief Scientific Officer of Rezo Therapeutics
- Dr. Guiducci brings nearly 20 years of oncology and immunology research experience
- Former SVP of Immunology and Oncology Research at Nurix Therapeutics
- Expert in drug discovery and building foundational research teams
- Rezo’s platform integrates AI and machine learning for precision therapeutics
Source: Business Wire
Notable Quotes
- “Cristiana brings deep scientific experience in drug discovery and has important expertise in building foundational research teams, identifying drug candidates and laying the groundwork for clinical advancement.” — Nevan Krogan, Ph.D., president and co-founder at Rezo Therapeutics
- “After spending my career embedded in advancing research across oncology and autoimmune diseases, I’m looking forward to joining Rezo and contributing to its integrated approach to drug discovery.” — Cristiana Guiducci, Ph.D., Chief Scientific Officer at Rezo Therapeutics
SoHC's Take
Rezo Therapeutics’ appointment of Dr. Cristiana Guiducci as Chief Scientific Officer marks a significant step forward in their mission to revolutionize drug discovery through integrated disease network mapping. Dr. Guiducci’s extensive background in oncology and immunology, combined with her leadership in drug discovery and development, will undoubtedly strengthen Rezo’s innovative approach. By leveraging AI and machine learning, Rezo is well-positioned to accelerate the identification of novel targets and therapies, potentially transforming the landscape of precision therapeutics. This strategic hire reflects Rezo’s commitment to advancing their scientific acumen and broadening their impact in the biotech industry.
